Top

Published in:

01-07-2012 | Research

Upregulation of Bone Morphogenetic Protein 4 is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma

Authors: Xiaodong Guo, Lu Xiong, Lin Zou, Jingmin Zhao

Published in: Pathology & Oncology Research | Issue 3/2012

Abstract

Bone morphogenetic protein (BMP) 4 plays a crucial role in tumor invasion and metastasis of various human cancers. However, little is known about the correlation of BMP4 expression with clinical aggressiveness and prognosis in hepatocellular carcinoma (HCC). The aim of this study was to investigate the expression of BMP4 in HCC and determine its correlation with tumor progression and prognosis. Immunohistochemistry assay was used to determine the expression of BMP4 in HCC and corresponding paracarcinomatous tissues from 156 patients. The potential prognostic value of BMP4 was investigated by comparing the survival rates between the BMP4-positive and BMP4-negative HCC patients. Immunohistochemically, BMP4 protein expression in the HCC tissues (120/156, 76.9%) was significantly higher than that in the paracarcinomatous tissues (19/156, 12.2%, P < 0.01). The expression of BMP4 in HCC was associated with number of tumor nodules (P = 0.02), Edmondson grade (P = 0.03), TNM stage (P = 0.009), and vascular invasion (P = 0.006). In univariate survival analysis, the significant associations of the BMP4 protein overexpression with shortened patients’ overall and disease-free survival were found (P = 0.001 and 0.006, respectively). Furthermore, its expression was found to be an independent factor for predicting both overall (P = 0.009) and disease-free survival (P = 0.022) of HCC in multivariate analysis. Our data suggest for the first time that BMP4 is overexpressed in HCC tissues and may also act as a novel marker for predicting the recurrence and prognosis of HCC patients after surgery.

Yang H, Lin M, Xiong F, Yang Y, Nie X, McNutt MA, Zhou R (2011) Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients. Surg Today 41:810–817PubMedCrossRef

Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674–687PubMedCrossRef

Thorgeirsson SS, Grisham JW (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31:339–346PubMedCrossRef

Chen D, Zhao M, Mundy GR (2004) Bone morphogenetic proteins. Growth Factors 22:233–241PubMedCrossRef

Simic P, Vukicevic S (2005) Bone morphogenetic proteins in development and homeostasis of kidney. Cytokine Growth Factor Rev 16:299–308PubMedCrossRef

Marki D, Celi T, Grkovi A, Spanjol J, Fukar Z, Grahovac B, Ethorevi G, Bobinac D (2011) mRNA expression of bone morphogenetic proteins and their receptors in human renal cell carcinoma. Urol Int In press

Yuen HF, Chan YP, Cheung WL, Wong YC, Wang X, Chan KW (2008) The prognostic significance of BMP-6 signaling in prostate cancer. Mod Pathol 21:1436–1443PubMedCrossRef

Motoyama K, Tanaka F, Kosaka Y, Mimori K, Uetake H, Inoue H, Sugihara K, Mori M (2008) Clinical significance of BMP7 in human colorectal cancer. Ann Surg Oncol 15:1530–1537PubMedCrossRef

Hogan BL (1996) Bone morphogenetic proteins in development. Curr Opin Genet Dev 6:432–438PubMedCrossRef

10.

Virtanen S, Alarmo EL, Sandström S, Ampuja M, Kallioniemi A (2011) Bone morphogenetic protein −4 and −5 in pancreatic cancer–novel bidirectional players. Exp Cell Res 317:2136–2146PubMedCrossRef

11.

McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S, Cabrera L, Keller E, McCauley L, Cho KR, Buckanovich RJ (2011) Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest 121:3206–3219PubMedCrossRef

12.

Slattery ML, Lundgreen A, Herrick JS, Kadlubar S, Caan BJ, Potter JD, Wolff RK (2011) Genetic variation in bone morphogenetic protein and colon and rectal cancer. Int J Cancer In press

13.

Qiao B, Johnson NW, Chen X, Li R, Tao Q, Gao J (2011) Disclosure of a stem cell phenotype in an oral squamous cell carcinoma cell line induced by BMP-4 via an epithelial-mesenchymal transition. Oncol Rep 26:455–461PubMed

14.

Ketolainen JM, Alarmo EL, Tuominen VJ, Kallioniemi A (2010) Parallel inhibition of cell growth and induction of cell migration and invasion in breast cancer cells by bone morphogenetic protein 4. Breast Cancer Res Treat 124:377–386PubMedCrossRef

15.

Shon SK, Kim A, Kim JY, Kim KI, Yang Y, Lim JS (2009) Bone morphogenetic protein-4 induced by NDRG2 expression inhibits MMP-9 activity in breast cancer cells. Biochem Biophys Res Commun 385:198–203PubMedCrossRef

16.

Hjertner O, Hjorth-Hansen H, Borset M, Seidel C, Waage A, Sundan A (2001) Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Blood 97:516–522PubMedCrossRef

17.

Maegdefrau U, Arndt S, Kivorski G, Hellerbrand C, Bosserhoff AK (2011) Downregulation of hemojuvelin prevents inhibitory effects of bone morphogenetic proteins on iron metabolism in hepatocellular carcinoma. Lab Invest In press

18.

Ishak KG, Anthony PP, Sobin LH (1994) Nonepithelial tumors. In: Ishak KG (ed) Histological typing of tumors of the liver. World Health Organization International Classification of Tumors. Springer, Berlin, pp 22–27

19.

Wittekind C (2006) Pitfalls in the classification of liver tumors. Pathologe 27:289–293PubMedCrossRef

20.

Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25:2586–2593PubMedCrossRef

21.

Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ (2008) High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 26:2707–2716PubMedCrossRef

22.

Shen H, Huang GJ, Gong YW (2003) Effect of transforming growth factor beta and bone morphogenetic proteins on rat hepatic stellate cell proliferation and trans-differentiation. World J Gastroenterol 9:784–787PubMed

23.

Slattery ML, Lundgreen A, Herrick JS, Wolff RK, Caan BJ (2011) Genetic variation in the transforming growth factor-β signaling pathway and survival after diagnosis with colon and rectal cancer. Cancer 117:4175–4183PubMedCrossRef

24.

Lombardo Y, Scopelliti A, Cammareri P, Todaro M, Iovino F, Ricci-Vitiani L, Gulotta G, Dieli F, de Maria R, Stassi G (2011) Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology 140:297–309PubMedCrossRef

25.

Lee YC, Cheng CJ, Bilen MA, Lu JF, Satcher RL, Yu-Lee LY, Gallick GE, Maity SN, Lin SH (2011) BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res 71:5194–5203PubMedCrossRef

26.

Capasso M, Ayala F, Russo R, Avvisati RA, Asci R, Iolascon A (2009) A predicted functional single-nucleotide polymorphism of bone morphogenetic protein-4 gene affects mRNA expression and shows a significant association with cutaneous melanoma in Southern Italian population. J Cancer Res Clin Oncol 135:1799–1807PubMedCrossRef

27.

Deng H, Ravikumar TS, Yang WL (2007) Bone morphogenetic protein-4 inhibits heat-induced apoptosis by modulating MAPK pathways in human colon cancer HCT116 cells. Cancer Lett 256:207–217PubMedCrossRef

28.

Hamada S, Satoh K, Hirota M, Fujibuchi W, Kanno A, Umino J, Ito H, Satoh A, Kikuta K, Kume K, Masamune A, Shimosegawa T (2009) Expression of the calcium-binding protein S100P is regulated by bone morphogenetic protein in pancreatic duct epithelial cell lines. Cancer Sci 100:103–110PubMedCrossRef

29.

Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H, Olivi A, Dimeco F, Vescovi AL (2006) Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444:761–765PubMedCrossRef

Title: Upregulation of Bone Morphogenetic Protein 4 is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
Authors: Xiaodong Guo
Lu Xiong
Lin Zou
Jingmin Zhao
Publication date: 01-07-2012
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 3/2012
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-011-9488-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

SAHA Inhibits the Growth of Colon Tumors by Decreasing Histone Deacetylase and the Expression of Cyclin D1 and Survivin

Uncommon Late Relapse of Angioimmunoblastic T-Cell Lymphoma after 16-Year Remission Period

Molecular Profiling of Parathyroid Hyperplasia, Adenoma and Carcinoma

Hodgkin’s Lymphoma Developed after Autologous Stem Cell Transplantation for Multiple Myeloma

Increased NDRG1 Expression is Associated with Advanced T Stages and Poor Vascularization in Non-small Cell Lung Cancer

Upregulation of a Disintegrin and Metalloprotease 8 Influences Tumor Metastasis and Prognosis in Patients with Osteosarcoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer